Drug Profile
Research programme: angiogenesis inhibitors - SUGEN/AbbVie
Alternative Names: Angiogenesis inhibitors research programme - SUGEN/AbbVie; Eye disorders therapy - SUGEN/AbbVie; Research programme: eye disorders therapy - SUGEN/AbbVieLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan; SUGEN
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 30 Apr 2003 No development reported - Preclinical for Eye disorders in USA (unspecified route)
- 16 Apr 2003 On 16 April 2003, Pharmacia Corporation was acquired by, and merged into, Pfizer